GlobeNewswire

Regentis Biomaterials Ltd. Announces Pricing of Initial Public Offering
04/12/2025
Herzliya, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair [...]
Mesoblast Participation at Piper Sandler Conference
04/12/2025
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its participation at the Piper Sandler 37 [...]
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025
04/12/2025
Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer’s disease by up to 8.3 years in low-amyloid group who started treatment at an early [...]
Mesa Laboratories, Inc. to Announce Third Quarter Results on February 3, 2026
03/12/2025
LAKEWOOD, Colo., Dec. 03, 2025 (GLOBE NEWSWIRE) -- - Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the third quarter of fiscal year 2026 at approximately 8:00 A.M. Eastern [...]
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
03/12/2025
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on December 1, 2025, the [...]
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025
03/12/2025
Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO and SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage [...]
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/12/2025
BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
HealthEquity Reports Third Quarter Ended October 31, 2025 Financial Results
03/12/2025
Highlights of the third quarter include: Revenue increased 7% to $322.2 million. Net income per diluted share rose to $0.59 from $0.06 one year ago, and non-GAAP net income per diluted share increased 29% to $1.01. [...]
Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes
03/12/2025
Media Release COPENHAGEN, Denmark; December 3, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) have closed their previously [...]
Most Popular Legal Steroids for Muscle Building from CrazyBulk: Legal Steroid Alternatives for Lean Muscle Growth and Cutting in 2026
03/12/2025
Most Popular Legal Steroids for Muscle Building from CrazyBulk: Best-Selling Steroid Alternatives for Lean Muscle Growth and Cutting in 2026 CrazyBulk has emerged as one of the most trusted names in the world of legal [...]
Novel Pharmaceutical Avextra Capsule Enhances Patient Experience and Treatment Acceptance
03/12/2025
With evidence-based clinical development and new pharmaceutical formulations, Avextra aims to increase patient experience and adherence Bensheim, Germany – 3. December 2025 – How can therapy with Cannabis-based [...]
Cosmos Health Launches Strategic Partnership With Prime Ledger to Transform $300M Treasury and Tokenize IP Assets
03/12/2025
CHICAGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced a long-term strategic [...]
Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners
03/12/2025
PARSIPPANY, NJ, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) (“Interpace” or the “Company”) today announced that it has fully repaid its outstanding term loan facility with BroadOak [...]
Wake Radiology UNC Health Rex Announces the Retirement of Body Imaging Radiologist Dr. Imre Gaal Jr.
03/12/2025
Raleigh, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Wake Radiology UNC Health Rex, the largest outpatient imaging provider in the Triangle, today announced the retirement of distinguished Body Imaging Radiologist Imre Gaal [...]
Nika Pharmaceuticals, Inc. (NIKA) Progress Update
03/12/2025
HENDERSON, Nev., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA ) appeared on The Street Reports podcast where CEO Dimitar Savov shared the progress the company has made thus far and outlined [...]
4D Path’s Physics-Inspired QPOR™ Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial
03/12/2025
Prospective-trial analysis published in the Journal of the National Cancer Institute predicts residual cancer burden from baseline H&E slides using fully automated, treatment predictive platform NEWTON, Mass., Dec. [...]
NMDP Hires New Philanthropic Leader to Accelerate Financial Giving and Research
03/12/2025
MINNEAPOLIS, Dec. 03, 2025 (GLOBE NEWSWIRE) -- NMDP SM , a global nonprofit leader in cell therapy, hired Jessica Kowal as chief philanthropy officer to lead the NMDP Foundation SM , which expands access to blood stem [...]
Carl H. Sharperson III Joins MATTER Board of Directors
03/12/2025
MINNEAPOLIS, MN , Dec. 03, 2025 (GLOBE NEWSWIRE) -- MATTER, a Minnesota-based global NGO, today announced the appointment of Carl H. Sharperson III to its Board of Directors. Sharperson currently serves as a Senior [...]
Elevar Therapeutics Announces Publication of CARES-310 Study Final Analysis in The Lancet Oncology
03/12/2025
Phase 3 trial assessed the efficacy and safety of Elevar’s rivoceranib in combination with camrelizumab as a first-line therapy for uHCC The combination continued to show clinically meaningful survival improvement [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum